ÂÜÀòÂÒÂ×

Dylan Morris is a General Partner in CRV's Bioengineering practice. He has led the fim's investments in Dyno Therapeutics, Deciduous Therapeutics, Plexium, System1 Biosciences, Recursion Pharmaceuticals, and 3T Biosciences. He previously invested at Innovation Endeavors, an early-stage venture firm backed by Eric Schmidt, of Google/Alphabet. At IE, Dylan drove investments in several companies operating at the intersection of computing and biology, including Freenome, a CRV portfolio company applying deep learning to liquid biopsy for early cancer detection. Previously, he co founded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Dylan conducted graduate research in Biophysics at Caltech and received an A.B. in Computer Science from Harvard.Dylan is passionate about accelerating the future of biology. He is excited about opportunities that leverage data to make biological engineering more tractable. He cares deeply about human health and is eager to explore creative ways to stimulate research and hasten the pace of biomedical innovation.